1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedarplus.ca under the Company’s profile.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
December 22, 2020
Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen
December 22, 2020
Resverlogix Files Notice of Annual and Special Meeting of Shareholders
November 20, 2020
Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
November 12, 2020
Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
November 2, 2020
A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
October 26, 2020
Resverlogix Announces Presentations at Leading Scientific Conferences
October 15, 2020
Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
October 14, 2020
Resverlogix Announces $13 Million Private Placement
October 6, 2020
Resverlogix Confirms Interim Filings on SEDAR
October 2, 2020
Resverlogix Provides Update Regarding Extension of its Filing Calendar
September 25, 2020
Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews
September 15, 2020
Resverlogix Provides Update Regarding Extension of its Filing Calendar
September 11, 2020
Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation
September 8, 2020
Resverlogix Provides Update Regarding Extension of its Filing Calendar
August 28, 2020
Resverlogix Announces Private Placement
August 14, 2020
Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
August 4, 2020
Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption
July 28, 2020
Resverlogix Secures One-Year Extension of Maturity Date of Debenture
July 22, 2020
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
June 22, 2020
Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress
June 9, 2020
Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020
June 5, 2020
Resverlogix Plans COVID-19 Clinical Trial Program Launch
June 1, 2020
Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology Virtual
March 31, 2020
Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association
March 30, 2020
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
March 24, 2020
Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research
March 23, 2020
Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
February 3, 2020
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
January 13, 2020